COPD activates bitter taste receptors, the target of asthma treatment

Published Date: 17 Mar 2023

Germany: Activation of bitter taste receptors opens lung pathways, making them potential targets for the treatment of chronic lung diseases...

Read Full News

Latest News

Nalbuphine Extended-Release Reduces Chronic Cough in IPF, with Philip Molyneaux, MBBS Philip Molyneaux, MBBS

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Achieving Clinical Remission in Asthma Care, With Linda Rogers, MD Linda Rogers, MD

Roger discusses how new therapies are transforming asthma treatment, enabling potential clinical remission.

Rewriting Airway Disease With Trait-Based Care: 2025’s Convergence of Asthma and COPD Management

Rewriting Airway Disease With Trait-Based Care: 2025’s Convergence of Asthma and COPD Management

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

How to Set a Biologic Strategy for Asthma, with Sara Assaf, MD Sara Assaf, MD

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Todays Updates

NeuroVoices: Robert Alexander, MD, on the Evolution of Antiamyloid Therapeutics in Alzheimer Disease Robert Alexander, MD, Isabella Ciccone, MPH

At CTAD 2025, the chief scientific officer at the Banner Alzheimer’s Institute discussed emerging antiamyloid therapies, clinical trial insights, and treatment duration in Alzheimer disease.

Neflamapimod Reduces Plasma GFAP in Dementia With Lewy Bodies, Showing Correlation With Clinical Improvement Marco Meglio

New data highlights neflamapimod's potential in reducing biomarkers and improving clinical outcomes for dementia with Lewy bodies, paving the way for Phase 3 trials.

CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease Marco Meglio

Semaglutide shows no significant impact on Alzheimer disease progression in large trials, despite some biomarker improvements and consistent safety profiles.

New Clarity AD Analysis Reveal How Lecanemab Engages and Clears Neurotoxic Protofibrils in Alzheimer Disease Isabella Ciccone, MPH

In a study presented at CTAD 2025, patients treated with lecanemab showed a 59% increase in cerebrospinal fluid protofibril concentration at 12 months and a 45% increase at 18 months.

Autologous Stem Cell Approach Shows Promising Early Phase 1 Data in Alzheimer Disease Marco Meglio

A groundbreaking phase 1 trial reveals promising results for a new stem cell therapy targeting Alzheimer disease, advancing to phase 2 studies.

PROTECT: Sparsentan Offers CV Protection Benefits as First-Line Therapy in IgAN Chee Kay Cheung, MBChB, PhD

Recurrent UTIs Linked to QOL Burden in Kidney Transplant Recipients

Recurrent UTIs Linked to QOL Burden in Kidney Transplant Recipients

Todays Updates

NeuroVoices: Robert Alexander, MD, on the Evolution of Antiamyloid Therapeutics in Alzheimer Disease Robert Alexander, MD, Isabella Ciccone, MPH

At CTAD 2025, the chief scientific officer at the Banner Alzheimer’s Institute discussed emerging antiamyloid therapies, clinical trial insights, and treatment duration in Alzheimer disease.

Neflamapimod Reduces Plasma GFAP in Dementia With Lewy Bodies, Showing Correlation With Clinical Improvement Marco Meglio

New data highlights neflamapimod's potential in reducing biomarkers and improving clinical outcomes for dementia with Lewy bodies, paving the way for Phase 3 trials.

CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease Marco Meglio

Semaglutide shows no significant impact on Alzheimer disease progression in large trials, despite some biomarker improvements and consistent safety profiles.

New Clarity AD Analysis Reveal How Lecanemab Engages and Clears Neurotoxic Protofibrils in Alzheimer Disease Isabella Ciccone, MPH

In a study presented at CTAD 2025, patients treated with lecanemab showed a 59% increase in cerebrospinal fluid protofibril concentration at 12 months and a 45% increase at 18 months.

Autologous Stem Cell Approach Shows Promising Early Phase 1 Data in Alzheimer Disease Marco Meglio

A groundbreaking phase 1 trial reveals promising results for a new stem cell therapy targeting Alzheimer disease, advancing to phase 2 studies.

PROTECT: Sparsentan Offers CV Protection Benefits as First-Line Therapy in IgAN Chee Kay Cheung, MBChB, PhD

Recurrent UTIs Linked to QOL Burden in Kidney Transplant Recipients

Recurrent UTIs Linked to QOL Burden in Kidney Transplant Recipients

Latest News

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Roger discusses how new therapies are transforming asthma treatment, enabling potential clinical remission.

Rewriting Airway Disease With Trait-Based Care: 2025’s Convergence of Asthma and COPD Management

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

News All Time

Opportunities to Define and Treat Indoor Air Quality, with Sarath Raju, MD, MPH Sarath Raju, MD, MPH

Most clinicians are not considering poor home air exposure when treating persistent asthma or airway disease, Raju explains. That may be making a difference in outcomes.

Dupilumab, Tezepelumab Provide Consistent Real-World Severe Asthma Outcomes Kevin Kunzmann

Retrospective cohort data at CHEST 2025 show the similar efficacy profiles — but slightly different safety outcomes — among patients receiving either biologic.

The Case for More Spirometry, Pulmonary Function Testing, with Meredith McCormack, MD Kevin Kunzmann

McCormack believes simple lung function results accrued over a lifetime can optimize an individual's pulmonary care.

Clinical and Patient Definitions of Acute COPD Exacerbation Recovery Differ Greatly Kevin Kunzmann

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

What Ails Lung Cancer Screening, with Douglas Wood, MD Douglas Wood, MD

Wood shares 3 factors that influencing our nationally poor rates of high-risk lung cancer screening.

Guidelines in Review: CHEST Advises Against Routine Blood Transfusions for Critically Ill Patients During Procedures Kevin Kunzmann

Evidence-based guidelines from emphasize personalized transfusion strategies for critically ill patients, urging clinicians to avoid routine platelet and fresh frozen plasma transfusions during common procedures.

Dupilumab Lessens COPD Exacerbation Impact, with Nicola Hanania, MD, MS Nicola Hanania, MD, MS

Hanania discusses the pooled BOREAS and NOTUS post hoc data showing dupilumab protects lung function before and after COPD exacerbations.

Extended-Release Nalbuphine Improves Patient-Reported Refractory Chronic Cough Within 1 Week Imran Satia, MD, PhD

Imran Satia, MD, PhD, discusses promising phase 2A trial data showing quick and significant improvements in patients' perception of cough frequency and severity.

Baseline Type 2 Biomarkers Can Predict Asthma Remission with Dupilumab, with Mario Castro, MD, MPH Kevin Kunzmann

Castro discusses new data from CHEST 2025 showing the value of baseline blood eosinophils and FeNO in understanding potential dupilumab outcomes.

Dry Powder Treprostinil Tolerated Among Patients with PH-ILD, with Nicholas Kolaitis, MD Kevin Kunzmann

Kolaitis discussed interim findings from the ASCENT trial, which showed ability to increase treprostinil dosing while maintaining a safe and efficacious profile.

Dupilumab Reduces Mucus Burden in Uncontrolled Asthma, with Njira Lugogo, MD Njira Lugogo, MD

Mucus plugs are an increasingly present issue in uncontrolled asthma. Lugogo discusses promising findings from VESTIGE that addresses them.

From Slowing Decline to Restoring Function: Taladegib’s Promise in IPF, With Toby Maher, MD, PhD Toby Maher, MD, PhD

Maher discussed taladegib's potential to improve FVC, rather than slow decline, in people with idiopathic pulmonary fibrosis.

Aroxybutynin and Atomoxetine (AD109) Reduces Obstructive Sleep Apnea Burden in Phase 3 SynAIRgy Kevin Kunzmann

Late-breaking data at CHEST 2025 support the novel combination therapy, which may be submitted to the FDA in application for patients with OSA in coming months.

Dupilumab Bests Omalizumab in Airway Improvement for Patients with CRSwNP and Asthma Kevin Kunzmann

Data from the phase 4 head-to-head EVEREST trial further indicates dupilumab's benefit for type 2 inflammatory airway disease.

Defining the Future of Asthma Remission, With Linda Rogers, MD

Defining the Future of Asthma Remission, With Linda Rogers, MD

The Asthma and COPD Precision Medicine Era, with Nicola A. Hanania, MD, MS

The Asthma and COPD Precision Medicine Era, with Nicola A. Hanania, MD, MS

Recommended News For You

Schizophrenia patients are motivated by music therapy.

AI Unlocks Benefits of Prostate Cancer Treatment.

Hydroxyurea Shows Some Benefits in Milder Sickle Cell Disease

Discovery of a new biomarker for early detection of bladder cancer in both dogs and humans

BlurryScope: A compact, AI-powered microscope for rapid, cost-effective cancer scoring

Aspirin for CRC Risk Reduction May Benefit Unhealthy People Most

New protocols, according to a study, allow many patients to safely return home one day after lung cancer surgery.

Recommended Articles For You

The Link Between Being Overweight and Cancer 

Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis 

Symptoms and Causes of Phlegmasia Cerulea Dolens: A Comprehensive Guide  

Understanding Hemosiderosis: Causes, Symptoms, and Treatment Options 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study: Rapamycin slows the progression of cancer by reducing aging and concentrating on precancerous cells.

2.

Make the Diagnosis: Can You Explain Her Rash and Conjunctival Injection?

3.

The American College of Physicians updated its recommendations for colorectal cancer screening.

4.

The September 2018 issue of Medical Bulletin.

5.

FDA Approves CAR-T Product Use for Myeloma Early.

1.

Cancer Rates on the Rise: What Can We Do to Stop It?

2.

Next-Gen Cancer Therapies: Radiopharmaceuticals, Immuno-Oncology, and Biologic Breakthroughs

3.

The Pros and Cons of Using Cyclophosphamide in Cancer Treatment 

4.

HPV Infection Review: Epidemiology, Risks, and Therapeutic Advances for Clinicians

5.

Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion

2.

The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift

3.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion

4.

Thromboprophylaxis In Medical Settings- An Update

5.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot